496:
3302:
42:
3312:
3338:
791:(CLL) are encouraging, with a 95% overall response rate demonstrating potential to become a best-in-class treatment for CLL. Notably, a 100% response rate was achieved for those people which were positive for the 17p13.1 gene deletion, a subgroup that typically results in a poor response to therapy and expected outcomes.
693:
The most common adverse events were headache, diarrhea and weight gain. Despite the appearance of a greater occurrence of transient headaches, data suggest a preferred advantage of acalabrutinib over ibrutinib due to expected reduced adverse events of skin rash, severe diarrhea, and bleeding risk.
779:
or otherwise virtually no inhibition on the kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1. In addition, in platelets treated with ibrutinib, thrombus formation was clearly inhibited while no impact to thrombus formation was identified relative to
660:
inhibitor. Acalabrutinib blocks an enzyme called Bruton's tyrosine kinase, which helps B cells to survive and grow. By blocking this enzyme, acalabrutinib is expected to slow down the build-up of cancerous B cells in CLL, thereby delaying progression of the cancer.
684:
In the United States, acalabrutinib is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
746:
purchased a 55% stake in Acerta Pharma for $ 4 billion in
December 2015, with an option to acquire the remaining 45% stake for an additional $ 3 billion, conditional on approval in both the US and Europe and the establishment of commercial opportunity.
780:
controls for those treated with acalabrutinib. These findings strongly suggest an improved safety profile of acalabrutinib with minimized adverse effects relative to ibrutinib. In pre-clinical studies, it was shown to be more potent and selective than
680:
for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL). It is also indicated for the treatment of adults with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.
1519:
607:
InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
219:
174:
565:
1512:
72:
3028:
1339:
579:
1505:
3213:
3373:
2511:
2154:
1453:
731:
949:
Text was copied from this source which is copyright
European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
2950:
787:
The interim results of the still on-going first human phase I/II clinical trial (NCT02029443) with 61 patients for the treatment of relapsed
1016:
1647:
3368:
860:
2625:
1424:
World Health
Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75".
3083:
3068:
756:
599:
2045:
1571:
838:
891:
270:
204:
104:
775:, acalabrutinib demonstrated higher selectivity and inhibition of the targeted activity of BTK, while having a much greater IC
3183:
1197:
1168:
3358:
3256:
3328:
123:
2391:
1203:
1174:
1022:
788:
719:
638:
376:
3378:
1548:
1313:
2572:
707:
Acalabrutinib was approved for medical use in the United States in 2017, and in the
European Union in November 2020.
664:
Acalabrutinib was approved for medical use in the United States in 2017, and in the
European Union in November 2020.
657:
1391:
2697:
2546:
2295:
1797:
760:
727:
2943:
2022:
1888:
1601:
1474:
1364:
1289:
1260:
1231:
935:
734:, WM). Approval would result in a 10-year period of market exclusivity for the stated indications within Europe.
723:
641:/small lymphocytic Lymphoma (CLL/SLL). It may be used both in relapsed as well as in treatment-naive settings.
2032:
1558:
1284:
1255:
1226:
3363:
3251:
1528:
160:
3315:
491:
3287:
3203:
3198:
3093:
2400:
1883:
1612:
959:
445:
3383:
3158:
3023:
1958:
1898:
1868:
1771:
1607:
1497:
677:
653:
3305:
2936:
1813:
1708:
1545:
1340:"AstraZeneca and Acerta Pharma's acalabrutinib tagged an Orphan Drug in Europe for three indications"
715:
634:
630:
1486:
2666:
1933:
1923:
1743:
645:
291:
167:
2321:
1953:
1938:
1858:
134:
742:
It was developed by Acerta Pharma. After promising results for CLL in initial clinical trials,
466:
425:
3043:
1998:
1399:
1150:
1084:
930:
456:
365:
243:
231:
54:
1053:
Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. (January 2016).
726:(EMA) Committee for Orphan Medicinal Products (COMP) for treatment of three indications: CLL/
300:
1838:
1680:
1675:
1433:
1140:
1130:
1074:
1066:
508:
385:
3342:
3173:
3013:
495:
2983:
2775:
2673:
2621:
2219:
1532:
1145:
1118:
1079:
1054:
3352:
3038:
2993:
2832:
2722:
2684:
2661:
2593:
2588:
2354:
2350:
2338:
2145:
1928:
1893:
1713:
1693:
991:
865:
808:
649:
484:
325:
96:
82:
834:
3282:
3228:
3218:
3148:
3058:
3008:
3003:
2872:
2857:
2827:
2807:
2689:
2637:
2598:
2486:
2465:
2372:
2334:
2235:
2210:
2206:
2090:
2055:
2008:
1993:
1948:
1823:
1793:
1718:
1536:
743:
673:
187:
182:
3223:
3178:
3168:
3163:
3143:
3138:
3123:
3118:
3103:
3073:
3033:
2988:
2978:
2959:
2902:
2882:
2877:
2867:
2847:
2822:
2817:
2800:
2748:
2738:
2733:
2728:
2630:
2557:
2527:
2522:
2517:
2501:
2491:
2471:
2346:
2342:
2330:
2326:
2255:
2159:
2105:
2100:
2065:
2003:
1988:
1978:
1973:
1968:
1963:
1943:
1908:
1863:
1843:
1833:
1788:
1753:
1733:
1689:
1652:
1640:
1635:
1597:
1581:
711:
90:
3208:
3193:
3153:
3133:
3113:
3098:
3053:
3048:
3018:
2917:
2912:
2887:
2852:
2837:
2812:
2795:
2785:
2743:
2714:
2679:
2645:
2562:
2552:
2532:
2496:
2481:
2476:
2446:
2380:
2376:
2358:
2306:
2285:
2245:
2240:
2179:
2110:
2085:
2060:
1983:
1918:
1878:
1873:
1853:
1848:
1828:
1818:
1808:
1723:
1703:
1685:
1593:
1135:
541:
356:
33:
1403:
3261:
3188:
3088:
3078:
3063:
2907:
2897:
2892:
2862:
2842:
2790:
2780:
2768:
2763:
2709:
2704:
2650:
2583:
2456:
2451:
2436:
2431:
2426:
2416:
2411:
2406:
2311:
2301:
2280:
2275:
2270:
2265:
2260:
2250:
2230:
2194:
2189:
2184:
2174:
2169:
2136:
2131:
2126:
2095:
2075:
2070:
1913:
1903:
1728:
1576:
781:
772:
76:
1154:
1088:
722:(CLL), and was similarly designated as an orphan medicinal product by the
672:
In the
European Union, acalabrutinib as monotherapy or in combination with
41:
1070:
3246:
3128:
3108:
2998:
2657:
2421:
2225:
2164:
2120:
2080:
2050:
1803:
1667:
1663:
1588:
336:
118:
17:
1438:
345:
1761:
311:
1119:"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor"
3266:
436:
730:(SLL), mantle cell lymphoma (MCL), and lymphoplasmacytic lymphoma (
405:
2641:
2367:
2201:
2150:
1630:
1055:"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia"
564:
555:
472:
416:
1017:"FDA approves new treatment for adults with mantle cell lymphoma"
2756:
2542:
2040:
1766:
1748:
1738:
1698:
1566:
396:
249:
2932:
1501:
237:
113:
2928:
213:
145:
226:
587:
CC#CC(=O)N1CCC1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5
644:
Common side effects include headaches, feeling tired,
3326:
886:
884:
1198:"Acalabrutinib Orphan Drug Designation and Approval"
1169:"Acalabrutinib Orphan Drug Designation and Approval"
3275:
3237:
2966:
2613:
2390:
2031:
2021:
1781:
1662:
1622:
1557:
1544:
553:
540:
507:
502:
483:
455:
435:
415:
395:
375:
355:
335:
310:
290:
261:
203:
198:
173:
159:
133:
103:
89:
71:
63:
53:
48:
892:"Calquence- acalabrutinib capsule, gelatin coated"
1365:"AstraZeneca to buy Acerta for blood cancer drug"
629:, is a medication used to treat various types of
925:
923:
921:
919:
917:
915:
913:
809:"Acalabrutinib (Calquence) Use During Pregnancy"
710:As of February 2016, acalabrutinib had received
324:
861:"Summary Basis of Decision (SBD) for Calquence"
299:
1371:. Chemistry World - Royal Society of Chemistry
2944:
1513:
8:
3029:Budesonide/glycopyrronium bromide/formoterol
122:
32:
1392:"AstraZeneca to Buy Stake in Acerta Pharma"
1048:
1046:
1044:
1042:
992:"Acalabrutinib Monograph for Professionals"
2951:
2937:
2929:
2028:
1554:
1520:
1506:
1498:
1112:
1110:
1108:
1106:
1104:
1102:
1100:
1098:
986:
984:
982:
980:
494:
364:
40:
1437:
1144:
1134:
1078:
384:
3333:
1390:Walker I, Roland D (17 December 2015).
800:
604:
584:
344:
275:
95:
485:
31:
714:designation in the United States for
465:
444:
424:
81:
7:
3311:
1123:Journal of Hematology & Oncology
964:Union Register of medicinal products
784:, the first-in-class BTK inhibitor.
471:
186:
1117:Wu J, Zhang M, Liu D (March 2016).
1059:The New England Journal of Medicine
404:
315:
278:4-{8-Amino-3-imidazopyrazin-1-yl}-
25:
3084:Glycopyrronium bromide/formoterol
757:international nonproprietary name
3336:
3310:
3301:
3300:
1027:(Press release). 31 October 2017
839:Therapeutic Goods Administration
732:Waldenström's macroglobulinaemia
525:
519:
960:"Calquence Product information"
612:Key:WDENQIQQYWYTPO-IBGZPJMESA-N
3374:Drugs developed by AstraZeneca
3184:Sodium zirconium cyclosilicate
531:
513:
1:
3257:Cambridge Antibody Technology
1338:House DW (25 February 2016).
1481:. National Cancer Institute.
1204:Food and Drug Administration
1175:Food and Drug Administration
1023:Food and Drug Administration
789:chronic lymphocytic leukemia
720:chronic lymphocytic leukemia
656:. It is a second generation
639:chronic lymphocytic leukemia
625:, sold under the brand name
3400:
3369:Tyrosine kinase inhibitors
2023:Tyrosine kinase inhibitors
761:United States Adopted Name
728:small lymphocytic lymphoma
503:Chemical and physical data
3296:
1889:Mirvetuximab soravtansine
1491:National Cancer Institute
1290:European Medicines Agency
1261:European Medicines Agency
1232:European Medicines Agency
1136:10.1186/s13045-016-0250-9
936:European Medicines Agency
724:European Medicines Agency
595:
575:
266:
39:
2033:Receptor tyrosine kinase
1559:Receptor tyrosine kinase
658:Bruton's tyrosine kinase
3252:Alexion Pharmaceuticals
1623:Others for solid tumors
1529:Targeted cancer therapy
282:-(2-pyridinyl)benzamide
3204:Trastuzumab deruxtecan
3199:Tixagevimab/cilgavimab
3094:Isosorbide mononitrate
1884:Loncastuximab tesirine
1613:Trastuzumab deruxtecan
3159:Salbutamol/budesonide
3024:Budesonide/formoterol
1959:Sacituzumab govitecan
1899:Moxetumomab pasudotox
1869:Inotuzumab ozogamicin
1772:Gemtuzumab ozogamicin
1608:Trastuzumab emtansine
1549:monoclonal antibodies
1533:antineoplastic agents
1071:10.1056/NEJMoa1509981
755:Acalabrutinib is the
654:low white blood cells
3359:Antineoplastic drugs
1814:Belantamab mafodotin
1426:WHO Drug Information
716:mantle cell lymphoma
635:mantle cell lymphoma
631:non-Hodgkin lymphoma
2667:Denileukin diftitox
2329:(ALK, ROS1, NTRK),
1934:Polatuzumab vedotin
1924:Oportuzumab monatox
1479:NCI Drug Dictionary
1396:Wall Street Journal
1314:"azn201602256k.htm"
698:Society and culture
646:low red blood cells
222:(Prescription only)
36:
3379:Alkyne derivatives
3240:acquired companies
2353:(ROS1, TRK, ALK),
1859:Enfortumab vedotin
1493:. 3 November 2017.
1459:. 27 January 2016.
898:. 22 November 2019
841:. 13 December 2019
3324:
3323:
3044:Disufenton sodium
2926:
2925:
2609:
2608:
2017:
2016:
1999:Tisotumab vedotin
869:. 23 October 2014
815:. 23 October 2019
620:
619:
566:Interactive image
253:
241:
229:
217:
149:
116:
27:Chemical compound
16:(Redirected from
3391:
3341:
3340:
3339:
3332:
3314:
3313:
3304:
3303:
3288:Louis Schweitzer
3238:Predecessors and
2953:
2946:
2939:
2930:
2640:peptide against
2213:(AXL, ALK, LTK))
2029:
1839:Dinutuximab beta
1555:
1522:
1515:
1508:
1499:
1494:
1482:
1461:
1460:
1458:
1450:
1444:
1443:
1441:
1421:
1415:
1414:
1412:
1410:
1387:
1381:
1380:
1378:
1376:
1361:
1355:
1354:
1352:
1350:
1335:
1329:
1328:
1326:
1324:
1310:
1304:
1303:
1301:
1299:
1281:
1275:
1274:
1272:
1270:
1252:
1246:
1245:
1243:
1241:
1223:
1217:
1216:
1214:
1212:
1194:
1188:
1187:
1185:
1183:
1165:
1159:
1158:
1148:
1138:
1114:
1093:
1092:
1082:
1050:
1037:
1036:
1034:
1032:
1013:
1007:
1006:
1004:
1002:
988:
975:
974:
972:
970:
956:
950:
948:
946:
944:
931:"Calquence EPAR"
927:
908:
907:
905:
903:
888:
879:
878:
876:
874:
857:
851:
850:
848:
846:
831:
825:
824:
822:
820:
805:
568:
548:
533:
527:
521:
515:
498:
487:
475:
469:
448:
428:
408:
388:
368:
348:
328:
318:
317:
303:
251:
248:
239:
236:
228:
225:
215:
212:
190:
147:
144:
126:
115:
112:
99:
85:
44:
37:
35:
21:
3399:
3398:
3394:
3393:
3392:
3390:
3389:
3388:
3349:
3348:
3347:
3337:
3335:
3327:
3325:
3320:
3292:
3271:
3239:
3233:
3174:Sebelipase alfa
3014:Brompheniramine
2962:
2957:
2927:
2922:
2776:Pi3K inhibitors
2674:mTOR inhibitors
2605:
2386:
2357:(VEGFR, FGFR),
2013:
1777:
1658:
1618:
1540:
1526:
1487:"Acalabrutinib"
1485:
1475:"Acalabrutinib"
1473:
1470:
1465:
1464:
1456:
1454:"Acalabrutinib"
1452:
1451:
1447:
1423:
1422:
1418:
1408:
1406:
1389:
1388:
1384:
1374:
1372:
1363:
1362:
1358:
1348:
1346:
1337:
1336:
1332:
1322:
1320:
1312:
1311:
1307:
1297:
1295:
1283:
1282:
1278:
1268:
1266:
1254:
1253:
1249:
1239:
1237:
1225:
1224:
1220:
1210:
1208:
1196:
1195:
1191:
1181:
1179:
1167:
1166:
1162:
1116:
1115:
1096:
1052:
1051:
1040:
1030:
1028:
1015:
1014:
1010:
1000:
998:
990:
989:
978:
968:
966:
958:
957:
953:
942:
940:
929:
928:
911:
901:
899:
890:
889:
882:
872:
870:
859:
858:
854:
844:
842:
833:
832:
828:
818:
816:
807:
806:
802:
797:
778:
769:
759:(INN), and the
753:
740:
705:
700:
691:
670:
616:
613:
608:
603:
602:
591:
588:
583:
582:
571:
546:
536:
530:
524:
518:
479:
451:
431:
411:
391:
371:
351:
331:
314:
306:
286:
283:
274:
273:
257:
194:
162:
155:
136:
129:
28:
23:
22:
15:
12:
11:
5:
3397:
3395:
3387:
3386:
3381:
3376:
3371:
3366:
3364:Human proteins
3361:
3351:
3350:
3346:
3345:
3322:
3321:
3319:
3318:
3308:
3297:
3294:
3293:
3291:
3290:
3285:
3279:
3277:
3273:
3272:
3270:
3269:
3264:
3259:
3254:
3249:
3243:
3241:
3235:
3234:
3232:
3231:
3226:
3221:
3216:
3211:
3206:
3201:
3196:
3191:
3186:
3181:
3176:
3171:
3166:
3161:
3156:
3151:
3146:
3141:
3136:
3131:
3126:
3121:
3116:
3111:
3106:
3101:
3096:
3091:
3086:
3081:
3076:
3071:
3066:
3061:
3056:
3051:
3046:
3041:
3036:
3031:
3026:
3021:
3016:
3011:
3006:
3001:
2996:
2991:
2986:
2984:Andexanet alfa
2981:
2976:
2970:
2968:
2964:
2963:
2958:
2956:
2955:
2948:
2941:
2933:
2924:
2923:
2921:
2920:
2915:
2910:
2905:
2900:
2895:
2890:
2885:
2880:
2875:
2870:
2865:
2860:
2855:
2850:
2845:
2840:
2835:
2830:
2825:
2820:
2815:
2810:
2805:
2804:
2803:
2798:
2793:
2788:
2783:
2773:
2772:
2771:
2766:
2753:
2752:
2751:
2746:
2741:
2736:
2731:
2723:CDK inhibitors
2719:
2718:
2717:
2712:
2707:
2694:
2693:
2692:
2687:
2682:
2670:
2654:
2634:
2622:fusion protein
2617:
2615:
2611:
2610:
2607:
2606:
2604:
2603:
2602:
2601:
2596:
2591:
2586:
2581:
2568:
2567:
2566:
2565:
2560:
2555:
2538:
2537:
2536:
2535:
2530:
2525:
2520:
2507:
2506:
2505:
2504:
2499:
2494:
2489:
2484:
2479:
2474:
2461:
2460:
2454:
2442:
2441:
2440:
2439:
2434:
2429:
2424:
2419:
2414:
2409:
2396:
2394:
2388:
2387:
2385:
2384:
2363:
2362:
2361:(VEGFR, EGFR).
2317:
2316:
2315:
2314:
2309:
2304:
2291:
2290:
2289:
2288:
2283:
2278:
2273:
2268:
2263:
2258:
2253:
2248:
2243:
2238:
2233:
2228:
2215:
2214:
2198:
2192:
2187:
2182:
2177:
2172:
2167:
2162:
2142:
2141:
2140:
2139:
2134:
2129:
2119:HER1/EGFR and
2115:
2114:
2108:
2103:
2098:
2093:
2088:
2083:
2078:
2073:
2068:
2063:
2058:
2053:
2037:
2035:
2026:
2019:
2018:
2015:
2014:
2012:
2011:
2006:
2001:
1996:
1991:
1986:
1981:
1976:
1971:
1966:
1961:
1956:
1951:
1946:
1941:
1936:
1931:
1926:
1921:
1916:
1911:
1906:
1901:
1896:
1891:
1886:
1881:
1876:
1871:
1866:
1861:
1856:
1851:
1846:
1841:
1836:
1831:
1826:
1821:
1816:
1811:
1806:
1801:
1798:+hyaluronidase
1791:
1785:
1783:
1779:
1778:
1776:
1775:
1758:
1757:
1731:
1726:
1721:
1716:
1711:
1706:
1672:
1670:
1660:
1659:
1657:
1656:
1644:
1638:
1626:
1624:
1620:
1619:
1617:
1616:
1610:
1605:
1602:+hyaluronidase
1585:
1579:
1563:
1561:
1552:
1542:
1541:
1527:
1525:
1524:
1517:
1510:
1502:
1496:
1495:
1483:
1469:
1468:External links
1466:
1463:
1462:
1445:
1416:
1382:
1356:
1330:
1305:
1285:"EU/3/16/1626"
1276:
1256:"EU/3/16/1625"
1247:
1227:"EU/3/16/1624"
1218:
1189:
1160:
1094:
1065:(4): 323–332.
1038:
1008:
976:
951:
939:. 20 July 2020
909:
880:
852:
826:
799:
798:
796:
793:
776:
768:
765:
752:
749:
739:
736:
704:
701:
699:
696:
690:
687:
669:
666:
618:
617:
615:
614:
611:
609:
606:
598:
597:
596:
593:
592:
590:
589:
586:
578:
577:
576:
573:
572:
570:
569:
561:
559:
551:
550:
544:
538:
537:
534:
528:
522:
516:
511:
505:
504:
500:
499:
489:
481:
480:
478:
477:
461:
459:
453:
452:
450:
449:
441:
439:
433:
432:
430:
429:
421:
419:
413:
412:
410:
409:
401:
399:
393:
392:
390:
389:
381:
379:
373:
372:
370:
369:
361:
359:
353:
352:
350:
349:
341:
339:
333:
332:
330:
329:
321:
319:
308:
307:
305:
304:
296:
294:
288:
287:
285:
284:
277:
269:
268:
267:
264:
263:
259:
258:
256:
255:
246:
234:
223:
209:
207:
201:
200:
196:
195:
193:
192:
179:
177:
171:
170:
165:
163:administration
157:
156:
154:
153:
151:
141:
139:
131:
130:
128:
127:
109:
107:
101:
100:
93:
87:
86:
79:
69:
68:
65:
61:
60:
57:
51:
50:
46:
45:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
3396:
3385:
3382:
3380:
3377:
3375:
3372:
3370:
3367:
3365:
3362:
3360:
3357:
3356:
3354:
3344:
3334:
3330:
3317:
3309:
3307:
3299:
3298:
3295:
3289:
3286:
3284:
3281:
3280:
3278:
3274:
3268:
3265:
3263:
3260:
3258:
3255:
3253:
3250:
3248:
3245:
3244:
3242:
3236:
3230:
3227:
3225:
3222:
3220:
3217:
3215:
3212:
3210:
3207:
3205:
3202:
3200:
3197:
3195:
3192:
3190:
3187:
3185:
3182:
3180:
3177:
3175:
3172:
3170:
3167:
3165:
3162:
3160:
3157:
3155:
3152:
3150:
3147:
3145:
3142:
3140:
3137:
3135:
3132:
3130:
3127:
3125:
3122:
3120:
3117:
3115:
3112:
3110:
3107:
3105:
3102:
3100:
3097:
3095:
3092:
3090:
3087:
3085:
3082:
3080:
3077:
3075:
3072:
3070:
3067:
3065:
3062:
3060:
3057:
3055:
3052:
3050:
3047:
3045:
3042:
3040:
3039:Dapagliflozin
3037:
3035:
3032:
3030:
3027:
3025:
3022:
3020:
3017:
3015:
3012:
3010:
3007:
3005:
3002:
3000:
2997:
2995:
2994:Asfotase alfa
2992:
2990:
2987:
2985:
2982:
2980:
2977:
2975:
2974:Acalabrutinib
2972:
2971:
2969:
2965:
2961:
2954:
2949:
2947:
2942:
2940:
2935:
2934:
2931:
2919:
2916:
2914:
2911:
2909:
2906:
2904:
2901:
2899:
2896:
2894:
2891:
2889:
2886:
2884:
2881:
2879:
2876:
2874:
2871:
2869:
2866:
2864:
2861:
2859:
2856:
2854:
2851:
2849:
2846:
2844:
2841:
2839:
2836:
2834:
2833:Larotrectinib
2831:
2829:
2826:
2824:
2821:
2819:
2816:
2814:
2811:
2809:
2806:
2802:
2799:
2797:
2794:
2792:
2789:
2787:
2784:
2782:
2779:
2778:
2777:
2774:
2770:
2767:
2765:
2762:
2761:
2760:
2758:
2754:
2750:
2747:
2745:
2742:
2740:
2737:
2735:
2732:
2730:
2727:
2726:
2725:
2724:
2720:
2716:
2713:
2711:
2708:
2706:
2703:
2702:
2701:
2699:
2695:
2691:
2688:
2686:
2685:Ridaforolimus
2683:
2681:
2678:
2677:
2676:
2675:
2671:
2668:
2664:
2663:
2659:
2655:
2652:
2648:
2647:
2643:
2639:
2635:
2632:
2628:
2627:
2623:
2619:
2618:
2616:
2612:
2600:
2597:
2595:
2594:Pirtobrutinib
2592:
2590:
2589:Orelabrutinib
2587:
2585:
2582:
2580:
2579:Acalabrutinib
2577:
2576:
2575:
2574:
2570:
2569:
2564:
2561:
2559:
2556:
2554:
2551:
2550:
2549:
2548:
2544:
2540:
2539:
2534:
2531:
2529:
2526:
2524:
2521:
2519:
2516:
2515:
2514:
2513:
2509:
2508:
2503:
2500:
2498:
2495:
2493:
2490:
2488:
2485:
2483:
2480:
2478:
2475:
2473:
2470:
2469:
2468:
2467:
2463:
2462:
2458:
2455:
2453:
2449:
2448:
2444:
2443:
2438:
2435:
2433:
2430:
2428:
2425:
2423:
2420:
2418:
2415:
2413:
2410:
2408:
2405:
2404:
2403:
2402:
2398:
2397:
2395:
2393:
2389:
2382:
2378:
2374:
2371:
2369:
2365:
2364:
2360:
2356:
2355:Selpercatinib
2352:
2351:Repotrectinib
2348:
2344:
2340:
2339:Larotrectinib
2336:
2332:
2328:
2325:
2323:
2319:
2318:
2313:
2310:
2308:
2305:
2303:
2300:
2299:
2298:
2297:
2293:
2292:
2287:
2284:
2282:
2279:
2277:
2274:
2272:
2269:
2267:
2264:
2262:
2259:
2257:
2254:
2252:
2249:
2247:
2244:
2242:
2239:
2237:
2234:
2232:
2229:
2227:
2224:
2223:
2222:
2221:
2217:
2216:
2212:
2208:
2204:
2203:
2199:
2196:
2193:
2191:
2188:
2186:
2183:
2181:
2178:
2176:
2173:
2171:
2168:
2166:
2163:
2161:
2157:
2156:
2152:
2147:
2146:RTK class III
2144:
2143:
2138:
2135:
2133:
2130:
2128:
2125:
2124:
2123:
2122:
2117:
2116:
2112:
2109:
2107:
2104:
2102:
2099:
2097:
2094:
2092:
2089:
2087:
2084:
2082:
2079:
2077:
2074:
2072:
2069:
2067:
2064:
2062:
2059:
2057:
2054:
2052:
2048:
2047:
2042:
2039:
2038:
2036:
2034:
2030:
2027:
2024:
2020:
2010:
2007:
2005:
2002:
2000:
1997:
1995:
1992:
1990:
1987:
1985:
1982:
1980:
1977:
1975:
1972:
1970:
1967:
1965:
1962:
1960:
1957:
1955:
1952:
1950:
1947:
1945:
1942:
1940:
1937:
1935:
1932:
1930:
1929:Pembrolizumab
1927:
1925:
1922:
1920:
1917:
1915:
1912:
1910:
1907:
1905:
1902:
1900:
1897:
1895:
1894:Mogamulizumab
1892:
1890:
1887:
1885:
1882:
1880:
1877:
1875:
1872:
1870:
1867:
1865:
1862:
1860:
1857:
1855:
1852:
1850:
1847:
1845:
1842:
1840:
1837:
1835:
1832:
1830:
1827:
1825:
1822:
1820:
1817:
1815:
1812:
1810:
1807:
1805:
1802:
1799:
1795:
1792:
1790:
1787:
1786:
1784:
1780:
1773:
1769:
1768:
1763:
1760:
1759:
1755:
1751:
1750:
1745:
1741:
1740:
1735:
1732:
1730:
1727:
1725:
1722:
1720:
1717:
1715:
1714:Mosunetuzumab
1712:
1710:
1707:
1705:
1701:
1700:
1695:
1694:Mosunetuzumab
1691:
1687:
1683:
1682:
1677:
1674:
1673:
1671:
1669:
1665:
1661:
1654:
1650:
1649:
1645:
1642:
1639:
1637:
1633:
1632:
1628:
1627:
1625:
1621:
1614:
1611:
1609:
1606:
1603:
1599:
1595:
1591:
1590:
1586:
1583:
1580:
1578:
1574:
1573:
1568:
1565:
1564:
1562:
1560:
1556:
1553:
1550:
1547:
1543:
1538:
1534:
1530:
1523:
1518:
1516:
1511:
1509:
1504:
1503:
1500:
1492:
1488:
1484:
1480:
1476:
1472:
1471:
1467:
1455:
1449:
1446:
1440:
1435:
1431:
1427:
1420:
1417:
1405:
1401:
1397:
1393:
1386:
1383:
1370:
1366:
1360:
1357:
1345:
1344:Seeking Alpha
1341:
1334:
1331:
1319:
1315:
1309:
1306:
1293:
1291:
1286:
1280:
1277:
1264:
1262:
1257:
1251:
1248:
1235:
1233:
1228:
1222:
1219:
1207:
1205:
1199:
1193:
1190:
1178:
1176:
1170:
1164:
1161:
1156:
1152:
1147:
1142:
1137:
1132:
1128:
1124:
1120:
1113:
1111:
1109:
1107:
1105:
1103:
1101:
1099:
1095:
1090:
1086:
1081:
1076:
1072:
1068:
1064:
1060:
1056:
1049:
1047:
1045:
1043:
1039:
1026:
1024:
1018:
1012:
1009:
997:
993:
987:
985:
983:
981:
977:
965:
961:
955:
952:
938:
937:
932:
926:
924:
922:
920:
918:
916:
914:
910:
897:
893:
887:
885:
881:
868:
867:
866:Health Canada
862:
856:
853:
840:
836:
830:
827:
814:
810:
804:
801:
794:
792:
790:
785:
783:
774:
766:
764:
762:
758:
750:
748:
745:
737:
735:
733:
729:
725:
721:
717:
713:
708:
702:
697:
695:
688:
686:
682:
679:
675:
667:
665:
662:
659:
655:
651:
650:low platelets
647:
642:
640:
636:
632:
628:
624:
623:Acalabrutinib
610:
605:
601:
594:
585:
581:
574:
567:
563:
562:
560:
557:
552:
545:
543:
539:
512:
510:
506:
501:
497:
493:
490:
488:
486:ECHA InfoCard
482:
474:
473:RCSB PDB
468:
463:
462:
460:
458:
454:
447:
446:ChEMBL3707348
443:
442:
440:
438:
434:
427:
423:
422:
420:
418:
414:
407:
403:
402:
400:
398:
394:
387:
383:
382:
380:
378:
374:
367:
363:
362:
360:
358:
354:
347:
343:
342:
340:
338:
334:
327:
323:
322:
320:
313:
309:
302:
298:
297:
295:
293:
289:
281:
276:
272:
265:
260:
254: Rx-only
247:
245:
235:
233:
224:
221:
211:
210:
208:
206:
202:
197:
189:
184:
181:
180:
178:
176:
172:
169:
166:
164:
158:
152:
143:
142:
140:
138:
132:
125:
124:Acalabrutinib
120:
111:
110:
108:
106:
102:
98:
94:
92:
88:
84:
80:
78:
74:
70:
66:
62:
58:
56:
52:
49:Clinical data
47:
43:
38:
34:Acalabrutinib
30:
19:
3384:Orphan drugs
3283:Tom McKillop
3229:Zolmitriptan
3219:Ximelagatran
3149:Rosuvastatin
3059:Esomeprazole
3009:Bicalutamide
3004:Benralizumab
2973:
2873:Pexidartinib
2858:Odronextamab
2828:Gilteritinib
2808:Cabozantinib
2755:
2721:
2696:
2690:Temsirolimus
2672:
2656:
2638:proapoptotic
2636:
2620:
2599:Zanubrutinib
2578:
2571:
2541:
2510:
2487:Lestaurtinib
2466:Janus kinase
2464:
2445:
2399:
2392:Non-receptor
2373:Cabozantinib
2366:
2335:Infigratinib
2320:
2294:
2236:Fruquintinib
2218:
2211:Gilteritinib
2207:Lestaurtinib
2200:
2149:
2118:
2091:Mobocertinib
2056:Aumolertinib
2044:
2009:Tremelimumab
1994:Tislelizumab
1949:Retifanlimab
1824:Blinatumomab
1794:Atezolizumab
1765:
1747:
1737:
1719:Obinutuzumab
1697:
1679:
1646:
1629:
1587:
1570:
1490:
1478:
1448:
1439:10665/331046
1429:
1425:
1419:
1407:. Retrieved
1395:
1385:
1373:. Retrieved
1368:
1359:
1347:. Retrieved
1343:
1333:
1321:. Retrieved
1317:
1308:
1296:. Retrieved
1294:. 4 May 2016
1288:
1279:
1267:. Retrieved
1265:. 4 May 2016
1259:
1250:
1238:. Retrieved
1236:. 2 May 2016
1230:
1221:
1209:. Retrieved
1201:
1192:
1180:. Retrieved
1172:
1163:
1126:
1122:
1062:
1058:
1029:. Retrieved
1020:
1011:
999:. Retrieved
995:
967:. Retrieved
963:
954:
941:. Retrieved
934:
900:. Retrieved
895:
871:. Retrieved
864:
855:
843:. Retrieved
829:
817:. Retrieved
812:
803:
786:
771:Relative to
770:
754:
744:Astra Zeneca
741:
709:
706:
703:Legal status
692:
689:Side effects
683:
674:obinutuzumab
671:
668:Medical uses
663:
643:
633:, including
626:
622:
621:
426:CHEBI:167707
301:1420477-60-6
279:
205:Legal status
199:Legal status
105:License data
29:
3224:Zafirlukast
3179:Selumetinib
3169:Saxagliptin
3164:Savolitinib
3144:Roflumilast
3139:Ravulizumab
3124:Palivizumab
3119:Osimertinib
3104:Motavizumab
3074:Fulvestrant
3034:Candesartan
2989:Anifrolumab
2979:Anastrozole
2960:AstraZeneca
2903:Tebentafusp
2883:Regorafenib
2878:Quizartinib
2868:Pemigatinib
2848:Midostaurin
2823:Erdafitinib
2818:Entrectinib
2801:Parsaclisib
2749:Trilaciclib
2739:Palbociclib
2734:Dalpiciclib
2729:Abemaciclib
2631:Aflibercept
2558:Entrectinib
2528:Selumetinib
2523:Cobimetinib
2518:Binimetinib
2502:Ruxolitinib
2492:Momelotinib
2472:Baricitinib
2370:inhibitors:
2347:Pralsetinib
2343:Pemigatinib
2331:Futibatinib
2327:Entrectinib
2324:inhibitors:
2256:Regorafenib
2160:Avapritinib
2106:Rociletinib
2101:Osimertinib
2066:Dacomitinib
2004:Toripalimab
1989:Teclistamab
1979:Talquetamab
1974:Tafasitamab
1969:Sugemalimab
1964:Serplulimab
1954:Sabatolimab
1944:Ramucirumab
1939:Prolgolimab
1909:Necitumumab
1864:Epcoritamab
1844:Dostarlimab
1834:Daratumumab
1789:Amivantamab
1754:Alemtuzumab
1744:Brentuximab
1734:Tositumomab
1709:Ibritumomab
1690:Elranatamab
1653:Bevacizumab
1641:Edrecolomab
1636:Catumaxomab
1598:Trastuzumab
1582:Panitumumab
1409:19 November
1375:24 December
1369:www.rsc.org
1349:21 November
1323:21 November
1318:www.sec.gov
943:11 November
902:11 November
835:"Calquence"
712:orphan drug
549: g·mol
492:100.247.121
262:Identifiers
91:MedlinePlus
64:Other names
55:Trade names
3353:Categories
3209:Vandetanib
3194:Ticagrelor
3154:Roxadustat
3134:Quetiapine
3114:Omeprazole
3099:Metoprolol
3054:Eculizumab
3049:Durvalumab
3019:Budesonide
2918:Venetoclax
2913:Vandetanib
2888:Ripretinib
2853:Nintedanib
2838:Lenvatinib
2813:Capmatinib
2796:Idelalisib
2786:Copanlisib
2759:inhibitors
2744:Ribociclib
2715:Vismodegib
2700:inhibitors
2680:Everolimus
2646:prohibitin
2563:Lorlatinib
2553:Crizotinib
2533:Trametinib
2497:Pacritinib
2482:Filgotinib
2477:Fedratinib
2381:Crizotinib
2377:Capmatinib
2359:Vandetanib
2307:Brigatinib
2286:Vandetanib
2246:Nintedanib
2241:Lenvatinib
2180:Ripretinib
2111:Vandetanib
2086:Lazertinib
2061:Brigatinib
1984:Tarlatamab
1919:Olaratumab
1879:Isatuximab
1874:Ipilimumab
1854:Elotuzumab
1849:Durvalumab
1829:Cemiplimab
1819:Bermekimab
1809:Axatilimab
1724:Ofatumumab
1704:Glofitamab
1686:Glofitamab
1594:Pertuzumab
795:References
637:(MCL) and
554:3D model (
542:Molar mass
457:PDB ligand
386:I42748ELQW
357:ChemSpider
292:CAS Number
271:IUPAC name
3262:MedImmune
3214:Vaxzevria
3189:Tamoxifen
3089:Goserelin
3079:Gefitinib
3064:Exenatide
2908:Tepotinib
2898:Sunitinib
2893:Sorafenib
2863:Pazopanib
2843:Masitinib
2791:Duvelisib
2781:Alpelisib
2769:Sotorasib
2764:Adagrasib
2710:Sonidegib
2705:Glasdegib
2651:Adipotide
2584:Ibrutinib
2457:Dasatinib
2452:Bosutinib
2437:Radotinib
2432:Ponatinib
2427:Nilotinib
2417:Dasatinib
2412:Bosutinib
2407:Asciminib
2375:(VEGFR),
2333:(FGFR2),
2312:Ceritinib
2302:Alectinib
2281:Toceranib
2276:Tivozanib
2271:Sunitinib
2266:Sorafenib
2261:Semaxanib
2251:Pazopanib
2231:Cediranib
2195:Toceranib
2190:Sunitinib
2185:Sorafenib
2175:Pazopanib
2170:Masitinib
2137:Tucatinib
2132:Neratinib
2127:Lapatinib
2096:Olmutinib
2076:Gefitinib
2071:Erlotinib
2046:HER1/EGFR
1914:Nivolumab
1904:Naxitamab
1729:Rituximab
1577:Cetuximab
1572:HER1/EGFR
1432:(1): 94.
1404:0099-9660
996:Drugs.com
845:31 August
813:Drugs.com
782:ibrutinib
773:ibrutinib
738:Economics
678:indicated
627:Calquence
161:Routes of
135:Pregnancy
83:Monograph
77:Drugs.com
59:Calquence
18:Calquence
3343:Medicine
3306:Category
3247:Astra AB
3129:Propofol
3109:Olaparib
2999:Atenolol
2967:Products
2698:hedgehog
2660:against
2658:exotoxin
2624:against
2573:Bruton's
2422:Imatinib
2345:(FGFR),
2341:(NTRK),
2226:Axitinib
2165:Axitinib
2121:HER2/neu
2081:Icotinib
2051:Afatinib
2025:("-nib")
1804:Avelumab
1676:lymphoid
1668:lymphoma
1664:Leukemia
1589:HER2/neu
1551:("-mab")
1298:15 April
1269:15 April
1240:15 April
1211:15 April
1182:15 April
1155:26957112
1089:26641137
1031:28 March
1001:16 March
896:DailyMed
819:28 March
767:Research
763:(USAN).
366:36764951
337:DrugBank
326:71226662
175:ATC code
168:By mouth
137:category
119:DailyMed
3316:Commons
3069:FluMist
2401:bcr-abl
1762:myeloid
1146:4784459
1080:4862586
969:3 March
547:465.517
509:Formula
346:DB11703
312:PubChem
230::
191:)
185: (
183:L01EL02
150: C
121::
97:a618004
67:ACP-196
3329:Portal
3276:People
3267:Zeneca
1648:VEGF-A
1402:
1153:
1143:
1129:: 21.
1087:
1077:
873:29 May
652:, and
580:SMILES
437:ChEMBL
406:D10893
244:â„ž-only
242:
232:â„ž-only
218:
117:
2642:ANXA2
2614:Other
2512:MAP2K
2383:(ALK)
2368:c-MET
2220:VEGFR
2155:PDGFR
2151:C-kit
1782:Other
1631:EpCAM
1457:(PDF)
1292:(EMA)
1263:(EMA)
1234:(EMA)
1206:(FDA)
1202:U.S.
1177:(FDA)
1173:U.S.
1025:(FDA)
1021:U.S.
751:Names
600:InChI
556:JSmol
464:XQQ (
417:ChEBI
2757:KRAS
2662:IL-2
2644:and
2626:VEGF
2543:EML4
2202:FLT3
2153:and
2041:ErbB
1767:CD33
1749:CD52
1739:CD30
1699:CD20
1567:ErbB
1411:2016
1400:ISSN
1377:2015
1351:2016
1325:2016
1300:2020
1271:2020
1242:2020
1213:2020
1184:2020
1151:PMID
1085:PMID
1033:2020
1003:2019
971:2023
945:2020
904:2020
875:2022
847:2024
821:2020
718:and
467:PDBe
397:KEGG
377:UNII
73:AHFS
2547:ALK
2447:Src
2322:RET
2296:ALK
1746:),
1736:),
1696:),
1681:CD3
1537:L01
1434:hdl
1141:PMC
1131:doi
1075:PMC
1067:doi
1063:374
676:is
316:CID
188:WHO
3355::
2379:,
2349:,
2337:,
2209:,
2148::
2043::
1764::
1692:,
1688:,
1678::
1596:,
1569::
1546:CI
1531:/
1489:.
1477:.
1430:30
1428:.
1398:.
1394:.
1367:.
1342:.
1316:.
1287:.
1258:.
1229:.
1200:.
1171:.
1149:.
1139:.
1125:.
1121:.
1097:^
1083:.
1073:.
1061:.
1057:.
1041:^
1019:.
994:.
979:^
962:.
933:.
912:^
894:.
883:^
863:.
837:.
811:.
777:50
648:,
523:23
517:26
470:,
250:EU
238:US
227:CA
220:S4
214:AU
146:AU
114:US
3331::
2952:e
2945:t
2938:v
2669:)
2665:(
2653:)
2649:(
2633:)
2629:(
2545:-
2459:)
2450:(
2205:(
2197:)
2158:(
2113:)
2049:(
1800:)
1796:(
1774:)
1770:(
1756:)
1752:(
1742:(
1702:(
1684:(
1666:/
1655:)
1651:(
1643:)
1634:(
1615:)
1604:)
1600:(
1592:(
1584:)
1575:(
1539:)
1535:(
1521:e
1514:t
1507:v
1442:.
1436::
1413:.
1379:.
1353:.
1327:.
1302:.
1273:.
1244:.
1215:.
1186:.
1157:.
1133::
1127:9
1091:.
1069::
1035:.
1005:.
973:.
947:.
906:.
877:.
849:.
823:.
558:)
535:2
532:O
529:7
526:N
520:H
514:C
476:)
280:N
252::
240::
216::
148::
75:/
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
